Phase II Study of Trastuzumab Biosimilar plus Gedatolisib in Patients with HER-2 Positive Metastatic Breast Cancer Who Progressed after 2 or more HER2 directed Chemotherapy [KM-10A/KCSG BR18-13]
구분
국외
국가
미국
컨퍼런스명
ASCO annual meeting 2025
발표 제목
Phase II Study of Trastuzumab Biosimilar plus Gedatolisib in Patients with HER-2 Positive Metastatic Breast Cancer Who Progressed after 2 or more HER2 directed Chemotherapy [KM-10A/KCSG BR18-13]